Home/Pipeline/Bevacizumab

Bevacizumab

Oncology

Not DisclosedActive

Key Facts

Indication

Oncology

Phase

Not Disclosed

Status

Active

Company

Epygen Biotech

About Epygen Biotech

Epygen Biotech is a private, US-based biopharmaceutical company founded in 2019, specializing in the development and manufacturing of biosimilar and novel therapeutic proteins. Its pipeline includes programs in oncology (Pegfilgrastim, Bevacizumab), cardiovascular (Recombinant Streptokinase), hormones (Teriparatide), and vaccines (SARS-CoV-2), supported by in-house CDMO capabilities. The company's strategy centers on leveraging its recombinant protein technology platform to produce high-quality, affordable biologics for global markets, though it appears to be in a pre-revenue or early development stage.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Immune disorders Vaccines

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active